373 results on '"Nuijten, Mark"'
Search Results
2. Are We Ready for a New Approach to Comparing Coverage and Reimbursement Policies for Medical Nutrition in Key Markets: An ISPOR Special Interest Group Report
3. Opportunities and Barriers to the Development and Use of Open Source Health Economic Models: A Survey
4. Replication of Published Health Economic Obesity Models: Assessment of Facilitators, Hurdles and Reproduction Success
5. Vitamin E and Healthcare Costs: Models to Assess the Impact
6. The impact of early phase price agreements on prices of orphan drugs
7. Health care costs matter: A review of nutrition economics
8. Economic viability of Stratified Medicine concepts: An investor perspective on drivers and conditions that favour using Stratified Medicine approaches in a cost-contained healthcare environment
9. Early phase value scan for biotechnology innovation
10. Clinical and economic issues complicating cost-effectiveness evaluation of orphan diseases
11. OP44 Does The Health Economic Modelling Structure Matter? An External Validation Of Three Approaches Commonly Used In Obesity Modelling
12. The Potential Impact of Current and Future Pharmaceutical Policy Changes on Cash Flows for Innovative Medicines
13. The Economic Value of Enteral Medical Nutrition in the Management of Disease-Related Malnutrition: A Systematic Review
14. Financial Valuation Algorithm for the Assessment of the Future Sales of a New, Innovative Medicinal Product
15. Pitfalls in the Valuation of a Pharmaceutical Company
16. An integrated valuation model for payer and investor
17. Opportunities and Barriers to the Development and Use of Open Source Health Economic Models: A Survey
18. The economic costs of disease related malnutrition
19. Modelling the burden of disease associated malnutrition
20. Health Economic Evaluation of Paricalcitol® Versus Cincalcet + Calcitriol (Oral) in Italy
21. Cost-Effectiveness of Escitalopram in Major Depressive Disorder in the Dutch Health Care Setting
22. Cost effectiveness of palivizumab in Spain: an analysis using observational data
23. Pricing matrix model: dealing with uncertainty
24. Pricing Zolgensma – the world’s most expensive drug
25. Health Economics in Medical Nutrition: An Emerging Science
26. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective
27. A Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer’s Perspective
28. Economic comments on proposal for a novel cancer drug pricing model
29. Probiotics and Cost-Benefits in the Prevention of Antibiotic-Associated Diarrhea: A New Dimension to Consider
30. Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria
31. Cost Effectiveness of Paricalcitol versus a Non-Selective Vitamin D Receptor Activator for Secondary Hyperparathyroidism in the UK: A Chronic Kidney Disease Markov Model
32. Cost Effectiveness of a Lidocaine 5% Medicated Plaster Compared with Pregabalin for the Treatment of Postherpetic Neuralgia in the UK: A Markov Model Analysis
33. Cost-Effectiveness Analysis of a Lidocaine 5% Medicated Plaster Compared with Gabapentin and Pregabalin for Treating Postherpetic Neuralgia: A German Perspective
34. Invited Speaker Text
35. Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children: A UK Analysis
36. Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis
37. Cost-Effectiveness of a Lidocaine 5% Medicated Plaster Relative to Gabapentin for Postherpetic Neuralgia in the United Kingdom
38. Economic Evaluation of Tramadol/ Paracetamol Combination Tablets for Osteoarthritis Pain in The Netherlands
39. Incorporation of Statistical Uncertainty in Health Economic Modelling Studies Using Second-Order Monte Carlo Simulations
40. Pricing of pharmaceuticals: Assessing the pricing potential by a pricing matrix model
41. Health care reform in six Central European countries: A focus on health economic requirements in the drug pricing and reimbursement processes
42. The incorporation of potential confounding variables in Markov models
43. Combining a Budgetary-Impact Analysis and a Cost-Effectiveness Analysis Using Decision-Analytic Modelling Techniques
44. Cost Effectiveness of Treatment of Parkinson’s Disease with Entacapone in the United States
45. Primary prevention of nephrolithiasis is cost-effective for a national healthcare system
46. A Cost-Cost Study Comparing Etanercept with Infliximab in Rheumatoid Arthritis
47. Cost Effectiveness of Emedastine versus Levocabastine in the Treatment of Allergic Conjunctivitis in 7 European Countries
48. Introduction to the Pharmacoeconomics of Herbal Medicines
49. Bridging Decision Analytic Modelling with a Cross-Sectional Study: Application to Parkinson’s Disease
50. Cost Effectiveness of Letrozole in the Treatment of Advanced Breast Cancer in Postmenopausal Women in the UK
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.